Subscribe to Search results

Dr Lane recorded that he proposed to the CBLA Scientific and Technical Committee in the spring of 1981 that a research project into the development of coagulation factor concentrates with reduced risk of hepatitis transmission was an appropriate project for central funding.

Published on:

A paper was produced by the Research and Development department of BPL, which noted that heating albumin products for such a period in the presence of a stabiliser had a "good record in the elimination of hepatitis virus infectivity" and that "If similar stabilisers can be established for coagulation factor products then heat inactivation will become the treatment of choice."

Published on:

A number of other possibilities for reducing the risk of hepatitis were canvassed by BPL 1981.

Published on:

Dr Smith visited PFC in Scotland and discussed research and development in respect of coagulation factors, and put forward to Dr Lane a "Proposal to Develop a 'Hepatitis-Safe' Factor VIII Concentrate".

Published on:

The draft proof of evidence of Dr Richard Lane expressed that "NANBH causes increasing concern, less on account of its acute effects (although deaths have been reported) than because of its association with chronic active hepatitis in later life", and that AIDS was "not yet proven to be of viral origin, but this is strongly presumed".

Published on:

Dr Smith proposed to make a special preparation of Factor 8 which would be subjected to dry heat (8CRV).

Published on:

Dr Smith was concerned that the few blood product recipients who had not already been infected with hepatitis might be engaged in testing other products to establish, for licensing authorities considering the grant of licences in respect of those products, whether they did, indeed, reduce non-A non-B Hepatitis as claimed.

Published on:

Dr Smith said that PFL/BPL had elected to try dry heating of an existing product, 8CRV. In the proposal he recognised "our late start."

Published on:

"The Lancet" published an article which in its summary said that the findings reported in it "support the possible role of retroviruses in AIDS, and indicate that factor VIII concentrates must be heated to inactivate these infectious viruses."

Published on:

Dr Lane wrote to Dr Edmund Harris at the DHSS to notify him of his plan to dry heat all the Factor 8 to be produced "on the empirical basis that it has a satisfactory process efficacy for inactivation of HTLV-III."

Published on:

Dr Harris asked Dr Lane to refer his plan to an advisory group to consider if the evidence for inactivation of HTLV-3 by heat was "sufficient to warrant" taking such a step, "particularly if a screening test can be made available."

Published on:

Dr Lane reported promising trials of a heat-treated product to the CBLA Central Committee for Research and Development in Blood Transfusion and that the time scale for the new product he had in mind ("8Y") was a year.

Published on:

Dr Lane's team gave him a "very provisional" date of 1 April 1985 for the implementation of heat treatment, and said it was "impossible to judge its feasibility."

Published on:

Dr Smith told Dr Lane: "US companies say they can provide UK with more than enough heated product, today."

Published on:

Dr Smith told Dr Lane: "Anything going into PFL's oven on 11th December will not be issuable until January", and asked if there should be an interim policy on the issue of "what little dry-heated 8CRV we already stock?"

Published on:

In an editorial "The Lancet" said that the time had come when it was now reasonable to switch to heat-treated products.

Published on:

Cutter and Alpha both published the results of tests which showed that their heating processes had inactivated HTLV-3/HIV virus load to a degree sufficient to show they were almost certainly (generally) safe, and the use of heat-treated product had been strongly endorsed by "The Lancet".

Published on:

Dr Snape wrote to the haemophilia centre directors to inform them that "limited supplies" of a heated Factor 8 concentrate would be available in early February and that would be "the product generally available for the next three to four months, the amounts being 50-60% of what would otherwise have been supplied as unheated concentrate."

Published on:

BPL had started to heat treat its Factor 8 and "limited amounts will be distributed to the National Health Service for clinical trials within the next two weeks. Heat-treatment capacity is being increased, and it is hoped that, by April this year, all BPL factor VIII will be heat-treated."

Published on:

Dr Snape wrote to Dr Lane: "a significant number of HTLV-III Christmas disease patients, treated only with NHS IX and with no other risk factors, argues strongly for haste with manufacture of heated factor IX."

Published on: